Topic: vision restoration
The mean increase in visual acuity now stands at 23 letters, well above the level deemed clinically meaningful by the FDA.
The AAV gene therapy was no better than placebo at improving vision at 48 weeks, leading GenSight to look to future updates to salvage the study.
Around half the patients in the higher-doses cohorts experienced vision improvements, encouraging Nightstar to move NSR-RPGR into phase 2.
GenSight Biologics has raised €22.5 million to prepare to bring gene therapy GS010 to market in the U.S. and Europe.
Novartis Chairman Joerg Reinhardt is talking down the chances of a smart lens project it began with Google yielding anything incredible in the next few years.
Allergan has bought gene therapy startup RetroSense Therapeutics to gain an early clinical candidate to treat the rare vision disorder retinitis pigmentosa (RP).